Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
Gram-Negative Bacterial Infections
About this trial
This is an interventional treatment trial for Gram-Negative Bacterial Infections focused on measuring Bacterial Infections
Eligibility Criteria
Inclusion Criteria: Male or female subjects aged 18 years or older Isolation of a resistant gram-negative pathogen, eg, Enterobacter species, Acinetobacter baumannii, Klebsiella pneumoniae, or other resistant gram-negative pathogens, alone or as 1 isolate of a polymicrobial infection Resistant gram-negative organisms are defined by the likely presence of ESBL or related mechanisms which limit the therapeutic alternatives for the treatment of complicated infections Exclusion Criteria: Subjects with any concomitant condition or taking any concomitant medication that, in the opinion of the investigator, could preclude an evaluation of a response or make it unlikely that the contemplated course of therapy or follow-up assessment will be completed or that will substantially increase the risk associated with the subject's participation in this study Anticipated length of antibiotic therapy < 7 days Known or suspected hypersensitivity to tigecycline or other compounds related to this class of antibacterial agents (eg, tetracyclines, minocycline, doxycycline)